Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol SEMA3B contributors: mct/npt - updated : 16-11-2016
HGNC name sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B
HGNC id 10724
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • N terminal signal peptide
  • the SEMA domain containing about 14 cysteine residues
  • an Ig-like motif
  • a C terminal short basic domain
    • HOMOLOGY
    Homologene
    FAMILY
  • semaphorin family
    • CATEGORY secretory , tumor suppressor
    SUBCELLULAR LOCALIZATION extracellular
        intracellular
    intracellular,cytoplasm,organelle,membrane
    intracellular,cytoplasm,organelle,endoplasmic reticulum
    basic FUNCTION
  • repellent of the nerve growth cone guidance
  • inhibiting axonal extension by providing local signals to specify territories inaccessible for growing axons
  • may be involved in regulating cell-sorting in the formation and regeneration of the periodontal attachment structure (Lallier 2004)
  • can act as a tumor suppressor by inducing apoptosis either by reexpression in tumor cells or applied as a soluble ligand (Castro-rivera 2004)
  • angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases (Varshavsky 2008)
  • role of the PLXNA2 receptor in SEMA3A and SEMA3B signal transduction
    • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component
  • member of class 3 semaphorins (Koyama 2008)
    • INTERACTION
    DNA
    RNA
    small molecule
    protein
  • interacting with VEGF(compete with SEMA3B for binding on the cell surface and antagonizing the negative regulatory effect of SEMA3B on cell growth)
  • interacting with IGFBP6 (IGFBP6 is the effector of tumor suppressor activity of SEMA3B)(Koyama 2008)
  • interacting with VEGFA (VEGFA, produced by tumor cells, acts as an autocrine survival factor and SEMA3B mediates its tumor-suppressing effects, at least in part, by blocking this VEGF autocrine activity)(Castro-Rivera 2004)
    • cell & other
    REGULATION
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral   LOH    
    in breast and non-small cell lung cancer
    tumoral       loss of function
    by hypermethylation in non-small cell lung cancer
    tumoral     --low  
    by hypermethylation in hepatocellular carcinomas and cholangiocarcinomas
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
    Therapy target
    ANIMAL & CELL MODELS